Miles Wang, a researcher from OpenAI, is reportedly leaving the company to start a new AI drug discovery venture. The startup is in talks to secure approximately $200 million in funding at a $2 billion valuation, with Lightspeed Venture Partners potentially leading the round. This move underscores the growing investor interest in applying artificial intelligence to the life sciences and drug development sectors, following similar significant funding rounds for related companies. AI
IMPACT Signals continued strong investor appetite for AI applications in life sciences, potentially accelerating drug discovery timelines.
RANK_REASON Significant funding round and valuation for a new startup founded by a researcher from a major AI lab, indicating strong investor interest in AI for drug discovery.
Read on Mastodon — mastodon.social →
- Chai Discovery
- ChatGPT
- Google DeepMind
- Harvard University
- Isomorphic Labs
- Lightspeed
- Miles Wang
- OpenAI
- United States Food and Drug Administration
- drug discovery
- Josh Meier
- Lightspeed Venture Partners
- Startup
AI-generated summary · Google Gemini · from 5 sources. How we write summaries →
